Prescient Therapeutics Ltd
ASX:PTX
Intrinsic Value
Prescient Therapeutics Ltd. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one
PTX
stock under the Base Case scenario is
0.017
AUD.
Compared to the current market price of 0.059 AUD,
Prescient Therapeutics Ltd
is
Overvalued by 71%.
PTX's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
PTX or that its price is influenced by factors unrelated to fundamentals.
Prescient Therapeutics Ltd's market capitalization is 47.5m AUD.
PTX stock price is 0.059 AUD.
PTX stock (0.017 AUD) is 71% less than its price (0.059 AUD).
PTX. Open DCF Valuation
PTX stock (0.017 AUD) is 71% less than its price (0.059 AUD). Open Relative Valuation
PTX.
PTX's ROE (Return on Equity) has significantly decreased in the last 3 years from -20% to -31%, and is approaching profitability.
PTX's Revenue has grown by an exceptional 317% over the past 12 months.
PTX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -92% to -190%, and is approaching profitability.
PTX has negative Operating Income for the last twelve months.
PTX has negative Net Income for the last twelve months.
PTX's ROE (Return on Equity) for the past 12 months is negative and is equal to -31%.
PTX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -190%.
PTX has negative Free Cash Flow for the last twelve months.
PTX's Revenue has been growing by an exceptional 119% per year for the last 3 years.
PTX has negative three-year average ROE (Return on Equity): -27%. The company is not efficient at transforming stockholders' equity into net income.
PTX has negative three-year average ROIC (Return on Invested Capital): -129%. The company is not efficient at using invested capital to generate operating income.
PTX's short-term assets (23m AUD) exceed its short-term liabilties (1m AUD).
PTX's long-term assets (26m AUD) exceed its long-term liabilties (1m AUD).
PTX's D/E (Debt to Equity) is very low and is equal to 0.
PTX's Altman Z-Score is very high and is equal to 23.34.
Valuation Backtest
Prescient Therapeutics Ltd
Run backtest to discover the historical profit from buying and selling
PTX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Prescient Therapeutics Ltd
Balance Sheet Decomposition
Prescient Therapeutics Ltd
| Current Assets | 22.5m |
| Cash & Short-Term Investments | 21m |
| Receivables | 203.2k |
| Other Current Assets | 1.3m |
| Non-Current Assets | 3.4m |
| PP&E | 3.9k |
| Intangibles | 3.4m |
| Other Non-Current Assets | 10 |
| Current Liabilities | 1m |
| Accounts Payable | 855.8k |
| Accrued Liabilities | 118.2k |
| Other Current Liabilities | 56.8k |
| Non-Current Liabilities | 51.2k |
| Other Non-Current Liabilities | 51.2k |
Earnings Waterfall
Prescient Therapeutics Ltd
|
Revenue
|
697.9k
AUD
|
|
Operating Expenses
|
-8.4m
AUD
|
|
Operating Income
|
-7.7m
AUD
|
|
Other Expenses
|
-18.7k
AUD
|
|
Net Income
|
-7.7m
AUD
|
Free Cash Flow Analysis
Prescient Therapeutics Ltd
What is Free Cash Flow?
PTX Profitability Score
Profitability Due Diligence
Prescient Therapeutics Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Prescient Therapeutics Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
PTX Solvency Score
Solvency Due Diligence
Prescient Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Prescient Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PTX Price Targets Summary
Prescient Therapeutics Ltd
Shareholder Return
PTX Price
Prescient Therapeutics Ltd
| Average Annual Return | 67.8% |
| Standard Deviation of Annual Returns | 140.61% |
| Max Drawdown | -85% |
| Market Capitalization | 47.5m AUD |
| Shares Outstanding | 805 320 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Prescient Therapeutics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).
Contact
IPO
Employees
Officers
The intrinsic value of one
PTX
stock under the Base Case scenario is
0.017
AUD.
Compared to the current market price of 0.059 AUD,
Prescient Therapeutics Ltd
is
Overvalued by 71%.
You don't have any saved screeners yet
